MY133473A - Haterocyclic glycyl beta-alanine derivatives. - Google Patents

Haterocyclic glycyl beta-alanine derivatives.

Info

Publication number
MY133473A
MY133473A MYPI99001398A MYPI9901398A MY133473A MY 133473 A MY133473 A MY 133473A MY PI99001398 A MYPI99001398 A MY PI99001398A MY PI9901398 A MYPI9901398 A MY PI9901398A MY 133473 A MY133473 A MY 133473A
Authority
MY
Malaysia
Prior art keywords
haterocyclic
glycyl
beta
alanine derivatives
compounds
Prior art date
Application number
MYPI99001398A
Inventor
Nizal Samuel Chandrakumar
Julie M Miyashiro
Shashidhar N Rao
Joseph G Rico
Mark Andrew Russell
Yi Yu
Bipinchandra Nanubhai Desai
Balekudru Devadas
Alan Frank Gasiecki
Renee Huff
Thomas E Rogers
Peter G Ruminski
Ish K Khanna
James W Malecha
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of MY133473A publication Critical patent/MY133473A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

THE PRESENT INVENTION RELATES TO A CLASS OF COMPOUNDS REPRESENTED BY THE FORMULA I OR A PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATING CONDITIONS MEDIATED BY THE αvβ₃ INTEGRIN.
MYPI99001398A 1998-04-10 1999-04-10 Haterocyclic glycyl beta-alanine derivatives. MY133473A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8139498P 1998-04-10 1998-04-10

Publications (1)

Publication Number Publication Date
MY133473A true MY133473A (en) 2007-11-30

Family

ID=22163868

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI99001398A MY133473A (en) 1998-04-10 1999-04-10 Haterocyclic glycyl beta-alanine derivatives.

Country Status (17)

Country Link
EP (1) EP1070060A1 (en)
JP (1) JP2002511462A (en)
KR (1) KR20010042614A (en)
CN (1) CN1304406A (en)
AR (1) AR015759A1 (en)
AU (1) AU765294B2 (en)
BR (1) BR9910119A (en)
CA (1) CA2326665A1 (en)
CZ (1) CZ20003672A3 (en)
IL (1) IL138677A0 (en)
MY (1) MY133473A (en)
NO (1) NO20005084L (en)
NZ (1) NZ507292A (en)
PL (1) PL343406A1 (en)
RU (1) RU2215746C2 (en)
TW (1) TWI247008B (en)
WO (1) WO1999052896A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172256B1 (en) * 1998-03-04 2001-01-09 G.D. Searle & Co. Chiral-β-amino acid compounds and derivatives thereof
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
CZ20012320A3 (en) * 1998-12-23 2002-10-16 G. D. Searle & Co. Medicament containing cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy when treating neoplasia
CA2360305A1 (en) 1999-02-09 2000-08-17 Bristol-Myers Squibb Company Lactam inhibitors of fxa and method
GB9908355D0 (en) * 1999-04-12 1999-06-09 Rhone Poulenc Rorer Ltd Chemical compounds
TR200102959T2 (en) 1999-04-12 2002-04-22 Aventis Pharma Limited Bicyclic heteroaryl compounds substituted as integrin antagonists
RU2001132141A (en) * 1999-04-28 2004-03-20 БАСФ Акциенгезельшафт (DE) INTEGRIN RECEPTOR ANTAGONISTS
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
WO2001079173A2 (en) 2000-04-17 2001-10-25 Celltech R & D Limited Enamine derivatives as cell adhesion molecules
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
EP1289959A1 (en) * 2000-06-15 2003-03-12 Pharmacia Corporation Dihydrostilbene alkanoic acid derivatives useful as vitronectin antagonists
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
CA2417059A1 (en) 2000-08-02 2002-02-07 Celltech R&D Limited 3-substituted isoquinolin-1-yl derivatives
DE10204789A1 (en) * 2002-02-06 2003-08-14 Merck Patent Gmbh Inhibitors of the integrin alpha¶v¶beta6
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
CA2510050A1 (en) * 2002-12-20 2004-07-22 Pharmacia Corporation The r-isomer of beta amino acid compounds as integrin receptor antagonists derivatives
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
EP2065381A1 (en) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP antagonists
EP2205599B1 (en) 2007-10-18 2012-06-06 Boehringer Ingelheim International GmbH Cgrp antagonists
CA2705599A1 (en) * 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh New compounds
US8829006B2 (en) 2007-11-22 2014-09-09 Boehringer Ingelheim International Gmbh Compounds
CN104640857B (en) 2012-07-18 2017-07-04 圣路易斯大学 As the beta amino acids derivative of integrin antagonists
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
KR20160147007A (en) 2014-05-30 2016-12-21 화이자 인코포레이티드 Carbonitrile derivatives as selective androgen receptor modulators
SG11201805387RA (en) 2015-12-30 2018-07-30 Univ Saint Louis Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
EA201991124A1 (en) * 2016-11-08 2019-10-31 Pyrrole amides as αV integrin inhibitors
MX2022014200A (en) * 2020-05-14 2022-12-07 Ube Corp 1, 4, 5, 6-tetrahydropyrimidine-2-amine derivative.
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators
JPWO2023085396A1 (en) * 2021-11-12 2023-05-19
CN115626912B (en) * 2022-09-27 2024-03-26 中山大学 Thiourea compound and preparation method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120859A (en) * 1989-09-22 1992-06-09 Genentech, Inc. Chimeric amino acid analogues
ATE203234T1 (en) * 1995-08-30 2001-08-15 Searle & Co META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINOBENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS
DE19629816A1 (en) * 1996-07-24 1998-01-29 Hoechst Ag New cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists
AU724191B2 (en) * 1996-08-29 2000-09-14 Merck & Co., Inc. Integrin antagonists

Also Published As

Publication number Publication date
KR20010042614A (en) 2001-05-25
RU2215746C2 (en) 2003-11-10
AU3449999A (en) 1999-11-01
NO20005084L (en) 2000-11-27
EP1070060A1 (en) 2001-01-24
PL343406A1 (en) 2001-08-13
AR015759A1 (en) 2001-05-16
BR9910119A (en) 2001-10-09
JP2002511462A (en) 2002-04-16
TWI247008B (en) 2006-01-11
NZ507292A (en) 2003-12-19
CN1304406A (en) 2001-07-18
IL138677A0 (en) 2001-10-31
CZ20003672A3 (en) 2001-08-15
WO1999052896A1 (en) 1999-10-21
AU765294B2 (en) 2003-09-11
NO20005084D0 (en) 2000-10-09
CA2326665A1 (en) 1999-10-21

Similar Documents

Publication Publication Date Title
MY133473A (en) Haterocyclic glycyl beta-alanine derivatives.
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
ATE203515T1 (en) META-SUBSTITUTED PHENYLSULPHONAMIDE DERIVATIVES
IL136044A (en) 2-aminoacetamide derivatives and pharmaceutical compositions containing the same
ES2182852T3 (en) PROLINAMIDE DERIVATIVES
GB9914486D0 (en) Medicaments
DK0889875T3 (en) Cycloproylalkanoic acid derivatives
YU69902A (en) New piperazine derivatives
DE69831868D1 (en) Antithrombosemittel
DK0889877T3 (en) Meta-substituted phenylene derivatives and their use as alpha-beta3 integrin antagonists or inhibitors
TR200200579T2 (en) Amino-thyrazolpyridine derivatives.
BR0212042A (en) Compound, pharmaceutical composition, method of treating or preventing disease, and use of a compound
DK0894084T3 (en) Cinnamic acid derivatives and their use as integrin antagonists
MXPA02003977A (en) INHIBITORS OF agr;L.
GEP20053617B (en) Bridged Piperazine Derivatives
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
HK1068332A1 (en) Pyrane derivatives as both ace-and nep-inhibitors
ATE266029T1 (en) SUBSTITUTED PYRROLOBENZIMIDAZOLE DERIVATIVES FOR ANTI-INFLAMMATORY
IL131216A (en) Drugs inhibiting progress of pterygium and postoperative recurrence of the same
FI970452A0 (en) Inhibition of leukotriene biosynthesis by urea derivatives
MX9703610A (en) Novel 2,3 disubstituted-(5,6)-heteroarylfused-pyrimidine-4-ones.
AP2001002179A0 (en) 2-Aminocarbonyl-9h-purine derivatives.